Serum Insulin-Like Growth Factor-I and Tumor Size in Patients with Metastatic Liver Cancer

authors:

avatar Mohsen Masoodi 1 , * , avatar Rahim Aghazadeh 2 , avatar Mohammad Hossein Somi 3 , avatar Ahmad Shavakhi 4 , avatar Abbas Arjmand Shabestari 2 , avatar Mohammad Reza Zali 2

Department of Internal Medicine, Hormozgan University of Medical Sciences, masoodi47@yahoo.com, Hormozgan, IR.Iran
Research Center for Gastroenterology & Liver Diseases (RCGLD), Shaheed Beheshti University of Medical Sciences, Tehran, IR.Iran
Tabriz Liver and Gastrointestinal Diseases Research Center (LGDRC), Tabriz University of Medical Sciences, Azarbayejan-e-Sharghi, IR.Iran
Isfahan University of Medical Sciences, Isfahan, IR.Iran
Hepatitis Monthly: Vol.8, issue 3; 179-183
article type: Research Article
received: November 20, 2007
accepted: August 26, 2008

How To Cite Masoodi M, Aghazadeh R, Somi M, Shavakhi A, Shabestari A, et al. Serum Insulin-Like Growth Factor-I and Tumor Size in Patients with Metastatic Liver Cancer. Hepat Mon. 2008;8(3): 179-183. 

Abstract

Background and Aims: Insulin-like growth factor-I (IGF-1) is a liver-derived humoral factor, which has important anabolic and metabolic actions. Low serum concentrations of IGF-1 have been reported in patients with chronic liver disease, especially cirrhosis and hepatocellular carcinoma and metastatic liver cancer. The aim of our study was to evaluate any possible relationship between intensity of liver metastases on serum IGF-1 concentrations.

Methods:  Serum IGF-1 were measured by ELIZA (III) in10 patients with uninodular or multinodular liver metastases and extension |£50% (group A) and 10 patients with multinodular or massive liver metastases and extension > 50% (group B) of liver size without liver failure.

Results: Serum IGF-1 concentration was significantly lower in the more sever metastatic group (group B) than the less sever metastatic group (group A) (121.40 ± 52.08 vs. 210.30 ± 42.59 ng/ml, respectively; P < 0.001).

Conclusions: Our findings suggest that the states of serum IGF-1 levels in patients with metastatic liver cancer may be a helpful finding for determining the severity of metastasis to the liver.

Full Text

Full text is available in PDF